Insmed Incorporated
INSM
株式のランク
#1107
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
株価
$95.88
最終同期: 2026-10-20
時価総額
$20.94B
変化（1日）
0.61%
変化（1年）
-42.00%
国
US
取引 Insmed Incorporated (INSM)
カテゴリー
Healthcare
Insmed Incorporated（INSM）の収益
Jun 2026 時点の収益 TTM: $1.14B
Insmed Incorporated の最新の財務報告によると、現在の収益 (TTM) は $1.14B です。2023 年には $305.21M の収益があり、これは 2022 年の $245.36M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Insmed Incorporated の収益履歴（2000 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.14B | 212.79% |
| 2024 | $363.71M | 19.17% |
| 2023 | $305.21M | 24.39% |
| 2022 | $245.36M | 30.19% |
| 2021 | $188.46M | 14.63% |
| 2020 | $164.41M | 20.48% |
| 2019 | $136.47M | 1,287.56% |
| 2018 | $9.84M | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | $11.50M | 0.00% |
| 2013 | $11.50M | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | $4.42M | -36.18% |
| 2010 | $6.92M | -33.28% |
| 2009 | $10.37M | -11.33% |
| 2008 | $11.70M | 55.39% |
| 2007 | $7.53M | 659.74% |
| 2006 | $991.00K | 656.49% |
| 2005 | $131.00K | -4.38% |
| 2004 | $137.00K | -8.67% |
| 2003 | $150.00K | -92.33% |
| 2002 | $1.96M | 560.47% |
| 2001 | $296.00K | 393.33% |
| 2000 | $60.00K | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 1,009.70% |
US
|
|
| $2.23B | 95.84% |
US
|
|
| $15.74B | 1,283.95% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 429.28% |
NL
|
